Home › Allergy › Massachusetts › Boston
Allergy clinical trials in Boston, MA
6 studies for Allergy are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Study of Oral Food Challenge Biomarkers (SAFER)
RecruitingObservational study
- Boston Children's Hospital: Allergy and Asthma Program, Boston
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
RecruitingPhase 2
- Massachusetts General Hospital, Boston
Registry of Asthma Characterization and Recruitment 3 (RACR3)
RecruitingObservational studyHealthy volunteers welcome
- Boston Children's Hospital: Department of Immunology, Boston
LYmph Node eXamination in Cat Allergen Immunotherapy
RecruitingEarly phase 1
- Brigham and Women's Hospital: Division of Allergy and Clinical Immunology, Boston
Omalizumab Weight-Based Dosing Efficacy Trial
RecruitingPhase 2
- Massachusetts General Hospital, Boston
About Allergy
An allergy is a reaction by your immune system. Substances that cause reactions include pollen and food. Find the full list of allergies and symptoms.
More about Allergy on MedlinePlus
Allergy trials in other cities
- New York City, NY6 studies
- Nashville, TN5 studies
- Washington, DC4 studies
- Ann Arbor, MI4 studies
- Mountain View, CA4 studies
- Baltimore, MD3 studies
- Chicago, IL3 studies
- Durham, NC3 studies
- Cincinnati, OH3 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.